Leisure Acquisition Corp. (ENSCW)

Overview

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company based in La Jolla, California, dedicated to innovating prescription drugs aimed at addressing severe pain management while combating opioid misuse, abuse, and overdose in the United States. Since its inception in 2003, Ensysce has focused on leveraging advanced prodrug technology platforms, namely Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), to develop safer opioid-based medications. These platforms serve as the foundation for the company's drug development endeavors, targeting both pain relief and the mitigation of opioid abuse risks.

Products and Services

• PF614 (TAAP Oxycodone Prodrug Candidate)

  A pioneering product in development utilizing the TAAP technology, PF614 is designed as an abuse-resistant oxycodone prodrug for patients suffering from acute or chronic pain. This extended-release formulation aims to provide effective pain relief with a significantly reduced risk of abuse and overdose.

• PF614-MPAR (Overdose Protection Product)

  Building on the abuse-resistant properties of PF614, PF614-MPAR combines PF614 with nafamostat to offer enhanced protection against overdose through excessive oral ingestion. This combination product underscores Ensysce's commitment to developing safer opioid medications by integrating overdose protection mechanisms.

• Nafamostat (Oral and Inhalation Drug)

  Alongside opioid-focused solutions, Ensysce is exploring the potential of nafamostat as an oral and inhalation therapeutic for combating coronaviral infections, including COVID-19, and other pulmonary conditions such as cystic fibrosis. This diversifies the company's portfolio into antiviral and respiratory treatments.

• PF329 (Pain Management with Abuse Protection)

  Ensysce is also developing PF329, an innovative product for pain management that embeds abuse protection features. This development signifies the company's ongoing efforts to introduce safer pain relief options into the market.

• PF8001 and PF8026 (Prodrugs of Amphetamine for ADHD)

  Expanding beyond pain management, Ensysce is working on PF8001 and PF8026, which are, respectively, extended and immediate-release prodrugs of amphetamine designed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). These formulations aim to offer therapeutic efficacy while minimizing abuse potential.

• PF9001 (Treatment for Opioid Use Disorder)

  With PF9001, Ensysce addresses opioid use disorder head-on, proposing an innovative treatment designed to offer relief from dependency within the framework of its abuse-deterrent technology. This initiative is part of the broader mission to provide comprehensive solutions in the realm of opioid management and treatment.